Freebird Partners LP has filed an amendment to its Schedule 13G, revealing its current beneficial ownership in Ernexa Therapeutics Inc. This update is significant as it indicates Freebird's continued investment in the pharmaceutical sector, specifically in a company that focuses on pharmaceutical preparations.

Freebird Partners LP, based in Houston, Texas, is a limited partnership that has shown active engagement in the market. The recent filing, made on October 30, 2026, highlights Freebird's ownership of 119,015 shares of Ernexa, which represents approximately 7% of the company's common stock. This stake is comprised of shares directly owned as well as those that can be acquired through warrants.

Background

Freebird Partners LP is a Texas limited partnership, with its principal business address located at 2800 Post Oak Blvd., Suite 2000, Houston, TX. The company primarily engages in investment activities. The recent filing is part of a series of updates, with the previous one submitted on May 15, 2026. Freebird's involvement in Ernexa is part of a broader trend in the pharmaceutical industry, where investments and ownership stakes are increasingly being consolidated among fewer players.

What the Filing Says

The filing states that Freebird Partners LP beneficially owns 119,015 shares of Ernexa Therapeutics, which includes shares from warrants. The document specifies, "This Amendment No. 7 to Schedule 13G amends the Schedule 13G filed by the Reporting Persons named therein on December 2, 2022, as amended and supplemented to date." This indicates a long-term interest in Ernexa, as Freebird has been updating its stake regularly.

Impact

This update may affect various stakeholders, including Ernexa's management, existing shareholders, and potential investors. With Freebird owning a notable percentage of Ernexa's stock, its decisions could influence the company's strategic direction and market performance. Additionally, competitors in the pharmaceutical preparations sector may need to adapt their strategies in response to Freebird's growing influence.

What's Next

The filing does not say what happens next. However, Freebird's ongoing updates suggest that it will continue to monitor and possibly increase its stake in Ernexa, depending on market conditions and the company's performance.